ID15999A - Antagonis oksitokin - Google Patents

Antagonis oksitokin

Info

Publication number
ID15999A
ID15999A IDP970772A ID970772A ID15999A ID 15999 A ID15999 A ID 15999A ID P970772 A IDP970772 A ID P970772A ID 970772 A ID970772 A ID 970772A ID 15999 A ID15999 A ID 15999A
Authority
ID
Indonesia
Prior art keywords
oxytocin antagonists
oxytocin
antagonists
Prior art date
Application number
IDP970772A
Other languages
English (en)
Indonesian (id)
Inventor
Hidenori Ogawa
Hisashi Miyamoto
Kazumi Kondo
Hiroshi Yamashita
Kenji Nakaya
Michinori Tanaka
Kazuyoshi Kitano
Keizo Kan
Michiaki Tominaga
Yoichi Yabuuchi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of ID15999A publication Critical patent/ID15999A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IDP970772A 1992-07-02 1997-03-11 Antagonis oksitokin ID15999A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17556692 1992-07-02
JP17556392 1992-07-02

Publications (1)

Publication Number Publication Date
ID15999A true ID15999A (id) 1997-08-21

Family

ID=26496804

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP970772A ID15999A (id) 1992-07-02 1997-03-11 Antagonis oksitokin

Country Status (8)

Country Link
EP (1) EP0602209A1 (fr)
CN (1) CN1091288A (fr)
AU (1) AU657424B2 (fr)
CA (1) CA2116334A1 (fr)
ID (1) ID15999A (fr)
MX (1) MX9304015A (fr)
TW (1) TW249201B (fr)
WO (1) WO1994001113A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356904A (en) * 1992-10-07 1994-10-18 Merck & Co., Inc. Carbostyril oxytocin receptor antagonists
GB9307527D0 (en) * 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
WO1995002405A1 (fr) * 1993-07-16 1995-01-26 Merck & Co., Inc. Benzoxasinone et benzopyrimidinone piperidinyle utiles comme antagonistes tocolytiques du recepteur de l'oxytocine
EP0805681A4 (fr) * 1995-01-24 1998-05-06 Merck & Co Inc Antagonistes tocolytiques des recepteurs de l'oxytocine
TW359669B (en) * 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
US5726172A (en) * 1996-01-16 1998-03-10 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
AR011913A1 (es) 1997-03-06 2000-09-13 Yamano Masaki Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
US6900200B2 (en) 2001-04-12 2005-05-31 Wyeth Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
US7109193B2 (en) 2001-04-12 2006-09-19 Wyeth Tricyclic diazepines tocolytic oxytocin receptor antagonists
US7326700B2 (en) 2001-04-12 2008-02-05 Wyeth Cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
US7202239B2 (en) 2001-04-12 2007-04-10 Wyeth Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists
US7064120B2 (en) 2001-04-12 2006-06-20 Wyeth Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
US7022699B2 (en) 2001-04-12 2006-04-04 Wyeth Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
US6977254B2 (en) 2001-04-12 2005-12-20 Wyeth Hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
GB0120051D0 (en) * 2001-08-16 2001-10-10 Ferring Bv Oxytocin agonists
US20050228016A1 (en) * 2002-06-13 2005-10-13 Enrique Michelotti Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex
KR20050029209A (ko) 2002-07-15 2005-03-24 미리어드 제네틱스, 인크. 화합물, 조성물 및 이의 사용방법
AU2003277285B2 (en) 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EP1554260A1 (fr) * 2002-10-22 2005-07-20 Glaxo Group Limited Derives d'aryloxyalkylamine tels que des ligands du recepteur h3
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
TWI322689B (en) 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
WO2006091674A1 (fr) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
WO2008141081A1 (fr) 2007-05-10 2008-11-20 Amr Technology, Inc. Tétrahydrobenzo-l,4-diazépines substituées par un aryle ou un hétéroaryle et utilisation desdites dans le blocage de la réassimilation de la norépinéphrine, de la dopamine et de la sérotonine
TWI459947B (zh) * 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑
CN102030709B (zh) * 2009-09-25 2013-10-16 江苏豪森医药集团有限公司 用作加压素受体拮抗剂的苯并氮杂卓类化合物
US9102669B2 (en) 2011-12-06 2015-08-11 Janssen Pharmaceutica Nv Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors
US9238658B2 (en) 2011-12-06 2016-01-19 Janssen Pharmaceutica Nv Substituted piperidinyl-carboxamide derivatives useful as SCD 1 inhibitors
US11690825B2 (en) 2016-03-09 2023-07-04 Board Of Regents, The University Of Texas System 20-HETE receptor (GPR75) antagonists and methods of use
WO2019003433A1 (fr) 2017-06-30 2019-01-03 大塚製薬株式会社 Dérivé de benzazépine
WO2020006497A1 (fr) * 2018-06-29 2020-01-02 Kinnate Biopharma Inc. Inhibiteurs de kinases dépendantes des cyclines
CN116472271A (zh) * 2020-11-26 2023-07-21 上海济煜医药科技有限公司 新型苯并氮杂卓螺环衍生物
CN112851583B (zh) * 2021-01-19 2023-09-08 徐州医科大学 新型苯并氮杂䓬类化合物、组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0382185T3 (da) * 1989-02-10 1994-07-04 Otsuka Pharma Co Ltd Carbostyrilderivater
CA2026856A1 (fr) * 1989-10-05 1991-04-06 Mark G. Bock Derives de substitution en 3 de 1,4-benzodiazepines, utiles comme oxytocine
EP0450097B1 (fr) * 1989-10-20 1996-04-24 Otsuka Pharmaceutical Co., Ltd. Composes benzoheterocycliques
TW199153B (fr) * 1990-08-07 1993-02-01 Dtsuka Seiyaku Kk

Also Published As

Publication number Publication date
MX9304015A (es) 1994-02-28
CN1091288A (zh) 1994-08-31
AU657424B2 (en) 1995-03-09
CA2116334A1 (fr) 1994-01-20
TW249201B (fr) 1995-06-11
WO1994001113A1 (fr) 1994-01-20
AU4356993A (en) 1994-01-31
EP0602209A1 (fr) 1994-06-22

Similar Documents

Publication Publication Date Title
ID15999A (id) Antagonis oksitokin
NO932005D0 (no) Angiotensin-ii-antagonister
EP0486280A3 (en) Piperidinylcamphorsulfonyl oxytocin antagonists
DK1066828T4 (da) Aerosolsammensætninger
NO930543D0 (no) Doseringsform
FI924405A (fi) Lhrh-antagonister
EP0729472A4 (fr) Antagonistes de l'oxytocine comprenant du piperidinylcamphosulfonyle
KR950703530A (ko) 5-HT4 길항제(5-HT4 Antagonists)
ATE172738T1 (de) Substituierte 6-aza-androstenone
FI952804A0 (fi) Substituoidut bentsatsepinonit
FI945889A (fi) Rekombinoitu ksylanaasi
EP0708765A4 (fr) Derives de piperazinylcamphre substitues en tant qu'antagonistes de l'ocytocine
NO944013D0 (no) Endothelin-antagonister II
FI104013B1 (fi) Suihkutuslaitteisto
NO862406D0 (no) Vasopressin-antagonister.
DE59309389D1 (de) Substituierte Thiophencarbonsäureamide
GB9306489D0 (en) Oxytocin antagonists
AT399791B (de) Stromrichter
EP0461707A3 (en) Peptide oxytocin antagonists
FI944307A (fi) Rakennusteline
DE69331261D1 (de) Hyperthermostabile beta-Galaktosidase
DE59310082D1 (de) Substituierte 2-arylpyrrole
KR940000134U (ko) 넥타이
KR100248605B1 (en) Oxytocin antagonist
DE69224296D1 (de) Baumaschine